Roche: Long-term Data Reinforces Benefit Of Early Initiation Of OCREVUS In Relapsing MS

Roche (RHHBY) reported long-term data that reinforced the benefit of early initiation and ongoing treatment of OCREVUS on disability progression in relapsing multiple sclerosis and primary progressive multiple sclerosis. The company noted that OCREVUS data from all trials consistently showed a favourable benefit-risk profile over eight years.

In phase III OPERA I and OPERA II open-label extension trial, earlier intervention with OCREVUS resulted in a 35% reduction in the risk of patients with relapsing multiple sclerosis needing a walking aid over seven and a half years compared with patients who switched from interferon beta-1a to OCREVUS after the 96-week double-blind period.

In phase III ORATORIO OLE trial, earlier intervention with OCREVUS resulted in a 29% reduction in 48-week confirmed disability progression in patients with primary progressive multiple sclerosis over eight years compared with patients who switched to OCREVUS from placebo after the double-blind period of at least 120 weeks.

Levi Garraway, Chief Medical Officer, said: "Additionally, the new safety analysis of the shorter two-hour OCREVUS infusion is encouraging particularly for groups that are often underrepresented in clinical trials."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Major covid vaccine makers said they are investigating Omicron, the new, heavily mutated coronavirus variant that was first detected in South Africa, and working to adapt their vaccines, if needed. The World Health Organization, which named the new variant omicron, said the new strain is a "variant of concern" that could pose a higher risk of reinfection compared to the previous mutations. This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3.
Follow RTT